| Name | Sulindac |
| Description | Sulindac (Sulindac sulfoxide) is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. |
| In vitro | In intestinal tissues of Min/+ mice, Sulindac does not alter the levels of PGE2 and LTB4 but reduces the number of tumors. Within a mouse model of familial adenomatous polyposis, Sulindac decreases small intestine COX-2 and prostaglandin E (2), thereby inhibiting tumor formation. |
| In vivo | In colorectal cancer (CRC) cell lines, Sulindac and its metabolites sulindac sulfide and sulindac sulfone inhibit the NF-κB pathway, reducing IKKbeta kinase activity mediated by Sulindac. In HT-29 cells, Sulindac significantly reduces cell growth. Sulindac inhibits cell proliferation across various epithelial and fibroblast tumor cell lines. In CRC cell lines DLD1 and SW480, Sulindac suppresses beta-catenin/TCF-mediated gene transcription and decreases levels of non-phosphorylated beta-catenin. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 9 mg/mL (25.25 mM)
DMSO : 50 mg/mL (140.29 mM)
|
| Keywords | epithelial-mesenchymal transition (EMT) | colorectal cancer (CRC) | pMMR | nonsteroidal | MK231 | SIRT1 | oral | inhibit | Nuclear factor-kappaB | TGF-β1 | migration | NSAID | anti-inflammatory | MK 231 | NF-κB | Nuclear factor-κB | lung cancer | invasion | Sulindac | Inhibitor | FDA | immunomodulatory agent |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Cosmetic Ingredient Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
